Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study
Authors:
- 1 November 2017
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 147 (2) , 257-261
Abstract
No abstract availableKeywords
Funding Information
- Canadian Partnership Against Cancer (CPAC) (CP432-2014-01)
This publication has 32 references indexed in Scilit:
- Comparative Study of Grade 3/4 Toxicity Associated With Intraperitoneal Chemotherapy Administered After Primary Versus Interval Surgical Debulking in Ovarian CancerInternational Journal of Gynecological Cancer, 2011
- When Should Surgical Cytoreduction in Advanced Ovarian Cancer Take Place?Journal of Oncology, 2009
- The Optimal Debulking after Neoadjuvant Chemotherapy in Ovarian Cancer: Proposal Based on Interval Look During Upfront Surgery Setting TreatmentJapanese Journal of Clinical Oncology, 2009
- Are Three Additional Cycles of Chemotherapy Useful in Patients with Advanced-stage Epithelial Ovarian Cancer After a Complete Response to Six Cycles of Intravenous Adjuvant Paclitaxel and Carboplatin?Japanese Journal of Clinical Oncology, 2008
- Timing of debulking surgery in advanced ovarian cancerInternational Journal of Gynecological Cancer, 2008
- Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patientsInternational Journal of Gynecological Cancer, 2008
- Maintenance or Consolidation Therapy in Advanced Ovarian CancerOncology, 2006
- A Prospective Randomized Comparison of 6 and 12 Cycles of Cyclophosphamide, Adriamycin, and Cisplatin in Advanced Epithelial Ovarian Cancer: A Danish Ovarian Study Group Trial (DACOVA)Gynecologic Oncology, 1993
- Adjuvant Therapy in Stage I and Stage II Epithelial Ovarian CancerNew England Journal of Medicine, 1990
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958